

Alessio Amatu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9575092/publications.pdf>

Version: 2024-02-01

73
papers

6,703
citations

136950

32
h-index

79698

73
g-index

76
all docs

76
docs citations

76
times ranked

9780
citing authors

#	ARTICLE	IF	CITATIONS
1	Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. <i>Nature Medicine</i> , 2015, 21, 795-801.	30.7	809
2	Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 738-746.	10.7	778
3	Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). <i>Cancer Discovery</i> , 2017, 7, 400-409.	9.4	647
4	Amplification of the <i>MET</i> Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. <i>Cancer Discovery</i> , 2013, 3, 658-673.	9.4	585
5	NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. <i>ESMO Open</i> , 2016, 1, e000023.	4.5	444
6	Adaptive mutability of colorectal cancers in response to targeted therapies. <i>Science</i> , 2019, 366, 1473-1480.	12.6	290
7	Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer. <i>Science Translational Medicine</i> , 2014, 6, 224ra26.	12.4	228
8	Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. <i>Gut</i> , 2018, 67, 1995-2005.	12.1	188
9	ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	183
10	Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer. <i>Annals of Oncology</i> , 2019, 30, viii5-viii15.	1.2	149
11	BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. <i>Annals of Oncology</i> , 2015, 26, 2092-2097.	1.2	137
12	Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer. <i>Cancer Cell</i> , 2018, 34, 148-162.e7.	16.8	129
13	Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type <i>KRAS</i> advanced biliary tract cancer: A randomized phase 2 trial (VICTORIA-BIL study). <i>Cancer</i> , 2016, 122, 574-581.	4.1	121
14	Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2016, 108, .	6.3	111
15	Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis. <i>Clinical Colorectal Cancer</i> , 2017, 16, e153-e163.	2.3	110
16	Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. <i>Annals of Oncology</i> , 2015, 26, 1994-1999.	1.2	105
17	Promoter CpG Island Hypermethylation of the DNA Repair Enzyme MGMT Predicts Clinical Response to Dacarbazine in a Phase II Study for Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 2265-2272.	7.0	96
18	HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2019, 24, 1395-1402.	3.7	95

#	ARTICLE	IF	CITATIONS
19	Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. <i>ESMO Open</i> , 2020, 5, e000911.	4.5	94
20	Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies. <i>Cancer Treatment Reviews</i> , 2019, 73, 41-53.	7.7	69
21	OEM-TACE: A New Therapeutic Approach in Unresectable Intrahepatic Cholangiocarcinoma. <i>CardioVascular and Interventional Radiology</i> , 2009, 32, 1187-1192.	2.0	66
22	A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin. <i>Clinical Cancer Research</i> , 2020, 26, 1372-1384.	7.0	66
23	Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer. <i>British Journal of Cancer</i> , 2015, 113, 1730-1734.	6.4	65
24	Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2020, 19, 256-262.e2.	2.3	56
25	Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients. <i>Cancer Discovery</i> , 2022, 12, 1656-1675.	9.4	48
26	The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer. <i>Cancers</i> , 2021, 13, 137.	3.7	46
27	Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line <i><i>RAS</i></i> Wild-Type Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 2276-2284.	7.0	45
28	Strategies to tackle RAS-mutated metastatic colorectal cancer. <i>ESMO Open</i> , 2021, 6, 100156.	4.5	38
29	Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer. <i>Cancer Treatment Reviews</i> , 2010, 36, S1-S5.	7.7	37
30	Clonally expanded EOMES+ Tr1-like cells in primary and metastatic tumors are associated with disease progression. <i>Nature Immunology</i> , 2021, 22, 735-745.	14.5	36
31	Transhepatic arterial chemoembolization with oxaliplatin-eluting microspheres (OEM-TACE) for unresectable hepatic tumors. <i>Anticancer Research</i> , 2008, 28, 3835-42.	1.1	36
32	Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer. <i>Annals of Oncology</i> , 2016, 27, 1062-1067.	1.2	35
33	The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives. <i>Cancer Treatment Reviews</i> , 2022, 104, 102351.	7.7	34
34	Tracking aCAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor. <i>Annals of Oncology</i> , 2017, 28, 1302-1308.	1.2	32
35	Oxaliplatin Immune-Induced Syndrome Occurs With Cumulative Administration and Rechallenge: Single Institution Series and Systematic Review Study. <i>Clinical Colorectal Cancer</i> , 2016, 15, 213-221.	2.3	31
36	Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities. <i>Cancer Treatment Reviews</i> , 2020, 91, 102112.	7.7	29

#	ARTICLE	IF	CITATIONS
37	Liquid biopsy for rectal cancer: A systematic review. <i>Cancer Treatment Reviews</i> , 2019, 79, 101893.	7.7	28
38	Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients. <i>European Journal of Cancer</i> , 2017, 71, 43-50.	2.8	27
39	Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3508-3508.	1.6	27
40	Validation of an LC-MS/MS method for the determination of epirubicin in human serum of patients undergoing Drug Eluting Microsphere-Transarterial Chemoembolization (DEM-TACE). <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 3543-3548.	2.3	25
41	Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT) <i>Tj ETQq1 1 04784314 rgBT /Overlock 10 T</i>	2.8	25
42	Complications of percutaneous radiofrequency thermal ablation of primary and secondary lesions of the liver. <i>Anticancer Research</i> , 2007, 27, 2911-6.	1.1	24
43	Pilot evaluation of scrambler therapy for pain induced by bone and visceral metastases and refractory to standard therapies. <i>Supportive Care in Cancer</i> , 2016, 24, 1649-1654.	2.2	23
44	High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib. <i>Frontiers in Oncology</i> , 2019, 9, 622.	2.8	22
45	Regorafenib in metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 255-265.	2.4	20
46	HER2 amplification as a "molecular bait" for trastuzumab-emtansine (T-DM1) precision chemotherapy to overcome anti-HER2 resistance in HER2 positive metastatic colorectal cancer: The HERACLES-RESCUE trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS774-TPS774.	1.6	18
47	Impaired seroconversion after SARS-CoV-2 mRNA vaccines in patients with solid tumours receiving anticancer treatment. <i>European Journal of Cancer</i> , 2022, 163, 16-25.	2.8	17
48	Phase II study of pertuzumab and trastuzumab-emtansine (T-DM1) in patients with HER2-positive metastatic colorectal cancer: The HERACLES-B (HER2 Amplification for Colo-rectal cancer Enhanced) <i>Tj ETQq0 0 0 rgBT /Overlock 10 T</i>	2.8	17
49	Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience. <i>Targeted Oncology</i> , 2017, 12, 525-533.	3.6	15
50	Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA. <i>Targeted Oncology</i> , 2021, 16, 309-324.	3.6	14
51	Liquid Biopsy for Small Cell Lung Cancer either De Novo or Transformed: Systematic Review of Different Applications and Meta-Analysis. <i>Cancers</i> , 2021, 13, 2265.	3.7	14
52	TRKA expression and <i>NTRK1</i> gene copy number across solid tumours. <i>Journal of Clinical Pathology</i> , 2018, 71, 926-931.	2.0	12
53	Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study. <i>ESMO Open</i> , 2021, 6, 100246.	4.5	11
54	Linitis Plastica of the Rectum As a Clinical Presentation of Metastatic Lobular Carcinoma of the Breast. <i>Journal of Clinical Oncology</i> , 2016, 34, e54-e56.	1.6	10

#	ARTICLE	IF	CITATIONS
55	Abstract CT110: Randomized phase II study of duligotuzumab + FOLFIRI versus cetuximab + FOLFIRI in 2nd-line patients with KRAS wild-type (wt) metastatic colorectal cancer (mCRC). <i>Cancer Research</i> , 2015, 75, CT110-CT110.	0.9	10
56	Intravenous or Oral Vinorelbine Plus Capecitabine As First-Line Treatment in HER2 ⁺ Metastatic Breast Cancer: Joint Analysis of 2 Consecutive Prospective Phase II Trials. <i>Clinical Breast Cancer</i> , 2012, 12, 30-39.	2.4	9
57	Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study. <i>Cancers</i> , 2022, 14, 1197.	3.7	9
58	Malignant mesothelioma of the tunica vaginalis testis in a petrochemical worker exposed to asbestos. <i>Anticancer Research</i> , 2008, 28, 1365-8.	1.1	6
59	Oxaliplatin-eluting microspheres for the treatment of intrahepatic cholangiocarcinoma: a case report. <i>Anticancer Research</i> , 2008, 28, 2987-90.	1.1	6
60	Empowering Clinical Decision Making in Oligometastatic Colorectal Cancer: The Potential Role of Drug Screening of Patient-Derived Organoids. <i>JCO Precision Oncology</i> , 2021, 5, 1192-1199.	3.0	5
61	Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study. <i>Supportive Care in Cancer</i> , 2021, 29, 3971-3980.	2.2	4
62	Aspirin for colorectal cancer with PIK3CA mutations: the rising of the oldest targeted therapy?. <i>Annals of Translational Medicine</i> , 2013, 1, 12.	1.7	4
63	Treatment of Chronic Hepatitis C in a Patient Affected by Systemic Sclerosis. <i>Gastroenterology Research and Practice</i> , 2009, 2009, 1-5.	1.5	3
64	Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer. <i>ESMO Open</i> , 2016, 1, e000079.	4.5	3
65	Acute Thrombocytopenia: An Unusual Complication Occurring After Drug-Eluting Microspheres Transcatheter Hepatic Chemoembolization. <i>CardioVascular and Interventional Radiology</i> , 2011, 34, 190-194.	2.0	2
66	507P Central nervous system recurrence in HER2-positive metastatic colorectal cancer. <i>Annals of Oncology</i> , 2020, 31, S455.	1.2	2
67	446P Bayesian monitoring of lapatinib (L) plus trastuzumab (T) treatment of HER2 positive metastatic colorectal cancer (mCRC): An observational cohort study. <i>Annals of Oncology</i> , 2021, 32, S557.	1.2	2
68	Is Codon 13 KRAS Mutation Biologically Different from Codon 12 Mutation?. <i>Current Colorectal Cancer Reports</i> , 2012, 8, 272-276.	0.5	1
69	Health-related quality of life in RAS wild-type metastatic colorectal cancer patients treated with panitumumab plus FOLFOX followed by panitumumab or panitumumab plus 5-FU/LV maintenance: the secondary endpoint of the Valentino study. <i>Annals of Oncology</i> , 2019, 30, iv115.	1.2	1
70	Seroconversion after SARS-CoV-2 mRNA booster vaccine in cancer patients. <i>European Journal of Cancer</i> , 2022, 167, 175-176.	2.8	1
71	Unusual Complication of Percutaneous Radiofrequency Thermal Ablation of Hepatic Tumor: The Split Electrode. <i>Journal of Vascular and Interventional Radiology</i> , 2008, 19, 625-626.	0.5	0
72	PD-006 Gemcitabine and Oxaliplatin (GEMOX) with or without Panitumumab as First-Line Treatment in Advanced Biliary Tract Cancer; final results and subgroup analysis of the Vecti-BIL Study. <i>Annals of Oncology</i> , 2015, 26, iv102.	1.2	0

#	ARTICLE	IF	CITATIONS
73	Multicenter randomized study of Gemcitabine and Oxaliplatin (GEMOX) +/- Panitumumab as First Line Treatment in K-Ras Wild type Advanced Biliary Tract Cancer; the VECTI-BIL study. <i>Annals of Oncology</i> , 2015, 26, vi90.	1.2	0